Mary L. (Nora) Disis, MD

Mary L. (Nora) Disis, MD

Director, Tumor Vaccine Medical Oncology
Department of Medicine
Division of Oncology

Mailing Address

Tumor Vaccine Group
815 Mercer Street
Seattle, WA 98109-4714

Admin Contact

Program Operations Specialist
Fax: 206.685.3128

Specialty / Expertise

Breast and Ovarian Cancer

Research Interests

Cancer vaccines and T-cell therapy
Cancer Immunodiagnostics

Current Research Projects

Please see www.tumorvaccinegroup.org


Dr. Disis graduated from the University of Nebraska Medical School and completed an Internal Medicine Residency and Chief Residency at the University of Illinois, Chicago, IL. She trained in Oncology at the University of Washington (UW) and Fred Hutchinson Cancer Research Center (FHCRC).

Selected Publications

Lu, H., Knutson, K.L., Gad, E., and Disis, M.L.: The tumor antigen repertoire identified in tumor bearing neu transgenic mice predicts human tumor antigens. Cancer Research, Oct. 1; 66(19):9754-61, 2006.

Dang, Y., Knutson, K.L., Goodell, V., delaRosa, C., Salazar, L.G., Higgins, D., Childs, J., and Disis, M.L.: Tumor antigen specific T cell expansion is greatly facilitated by in vivo priming. Clin Cancer Research, Mar 15; 13(6):1883-1891, 2007.

Inokuma, M., delaRosa, C., Schmitt, C., Haaland, P., Siebert, J., Petry, D., Tang, M.X., Suni, M.A., Ghanekar, S.A., Gladding, D., Dunne, J.F., Maino, V.C., Disis, M.L., and Maecker, H.T.: Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature, Journal of Immunology, 179:2627-2633, 2007.

Goodell, V., Waisman, J., Salazar, L.G., dela Rosa, C., Link, J., Coveler, A.L., Webster, W., Childs, J. S., Fintak, P.A., Higgins, D.M., and Disis, M.L. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Molecular Cancer Therapeutics, 7(3):449-54, 2008.

Maecker, H.T., Hassler, J., Payne, J.K., Summers, A., Comatas, K., Ghanayem, M., Morse, M.A., Clay, T.M., Lyerly, H.K., Bhatia, S., Ghanekar, S.A., Maino, V.C., delaRosa, C., and Disis, M.L.: Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunology, 9:9, 2008.

Park, K.H., Gad, E., Goodell, V., Dang, Y., Wild, T., Higgins, D. Fintak, P., Childs, J., delaRosa, C, and Disis, M.L.: Insulin like growth factor binding protein 2 is a target for the immunomodulation of breast cancer. Cancer Research, 68 (20):1-10, 2008.

Disis, M.L., Wallace, D. Gooley, T.A., Dang, Y., Slota, M., Lu, H., Coveler, A., Childs, J., Higgins, D., Fintak, P., delaRosa, C., Tietje, K., Link, J., Waisman, J., and Salazar, L.G.: Concurrent trastuzumab and HER-2/neu specific vaccination in patients with metastatic breast cancer. Journal of Clin Oncol, Oct 1;27(28):4685-4692, 2009.

Lu, H, Wagner, WM, Gad, E, Yang, Y, Duan, H, Amon, LM, Van Denend, N, Larson, ER, Chang, A, Tufvesson, H, and Disis, ML: Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade, J Immunol, 184 (9):5360-5367, 2010.

Last updated: August 2011